Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors
Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors
复制标题
DOI：
10.1161/01.atv.20.9.2156
复制
发表时间：
2000-09-01
影响因子：
8.7
通讯作者：
Alessi, MC
中科院分区：
文献类型：
--
作者：
Juhan-Vague, I;Renucci, JF;Alessi, MC
凝血酶可激活的纤维蛋白溶解抑制剂（TAFI）是最近描述的纤维蛋白溶解抑制剂，其作为羧肽酶原在血浆中循环并在凝血过程中转化为活性形式。TAFI的生理相关性尚不清楚，但它可能参与调节纤维蛋白沉积的途径。我们的目的是确定血浆TAFI抗原值的个体间变异性及其与传统心血管危险因素的相关性。626例连续患者（277名男性）参加代谢病房的一级预防进行了研究。TAFI抗原呈现出大范围的值，在第10次和第90次接种之间增加了2至3倍。两种性别之间未观察到差异。仅在女性中观察到年龄和TAFI水平之间存在显著相关性。调整年龄后，TAFI抗原在男性中与腰臀比和血压呈正相关，而在女性中没有观察到显著相关性。逐步多元线性回归分析表明，TAFI抗原水平的变异性研究的参数的贡献较低，腰臀围比仅占男性的2%，年龄仅占女性的3%。结果与纤维蛋白原和纤溶酶原激活物抑制剂-1进行比较;男性和女性的心血管危险因素分别占纤维蛋白原变异的16%和9.5%，分别占纤溶酶原激活物抑制剂-1变异的36%和32%。这些观察结果并未将生活方式特征在控制血浆中TAFI抗原浓度中的重要作用归因于生活方式特征。由于血浆中TAFI水平的个体间差异很大，可能涉及遗传控制。
Thrombin-activatable fibrinolysis inhibitor (TAFI) is a recently described fibrinolysis inhibitor that circulates in plasma as a procarboxypeptidase and is converted into an active form during coagulation. The physiological relevance of TAFI is not known, but it might be involved in pathways regulating fibrin deposition. Our aim was to determine the interindividual variability of plasma TAFI antigen values and their associations with conventional cardiovascular risk factors. Six hundred twenty-six consecutive patients (277 men) attending a metabolic ward for primary prevention were studied. TAFI antigen presented a large range of values, with a 2- to 3-fold increase between the 10th and 90th percentiles. No difference was observed between the 2 sexes. A significant correlation was observed between age and TAFI levels in women only. After adjustment for age, TAFI antigen was positively correlated in men for the waist-to-hip circumference ratio and blood pressure, whereas no significant correlation was observed in women. Stepwise multiple linear regression analysis indicated a low contribution of the parameters studied to the variability of TAFI antigen levels; the waist-to-hip circumference ratio accounted for only 2% in men, and age accounted for only 3% in women. Results were compared with those of fibrinogen and plasminogen activator inhibitor-1; cardiovascular risk factors in men and women accounted for 16% and 9.5%, respectively, of the fibrinogen variance and 36% and 32%, respectively, of the plasminogen activator inhibitor-1 variance. These observations did not attribute an important role to lifestyle characteristics in the control of TAFI antigen concentration in plasma. Because of the large interindividual variability of TAFI levels in plasma, genetic control may be involved.